Healthcare reality of the treatment of the high-risk multiple myeloma in Spain

被引：2
作者：
Hernandez-Rivas, Jose-Angel [1 ,2 ]
Gironella Mesa, Mercedes [3 ,4 ]
机构：
[1] Hosp Univ Infanta Leonor, Serv Hematol & Hemoterapia, Madrid, Spain
[2] Univ Complutense Madrid, Dept Med, Madrid, Spain
[3] Hosp Univ Vail dHebron, Serv Hematol, Barcelona, Spain
[4] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
来源：
MEDICINA CLINICA | 2020年 / 154卷 / 08期
关键词：
LENALIDOMIDE PLUS DEXAMETHASONE; TREATMENT STRATEGIES; CONSENSUS; STRATIFICATION; CARFILZOMIB; GUIDELINES; MANAGEMENT; SURVIVAL;
D O I：
10.1016/j.medcli.2019.10.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：315 / 319
页数：5
相关论文
共 50 条
[31]   Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study [J].
Zhan, Linquan ;
Yuan, Dai ;
Ge, Xueling ;
Ding, Mei ;
Wang, Jianhong ;
Zhou, Xiangxiang ;
Wang, Xin .
HEMATOLOGY, 2024, 29 (01)
[32]   Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients [J].
Ely, Scott ;
Forsberg, Peter ;
Ouansafi, Ihsane ;
Rossi, Adriana ;
Modin, Alvin ;
Pearse, Roger ;
Pekle, Karen ;
Perry, Arthur ;
Coleman, Morton ;
Jayabalan, David ;
Di Liberto, Maurizio ;
Chen-Kiang, Selina ;
Niesvizky, Ruben ;
Mark, Tomer M. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12) :825-833
[33]   Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future [J].
Landgren, Ola ;
Rajkumar, S. Vincent .
SEMINARS IN HEMATOLOGY, 2011, 48 (01) :66-72
[34]   A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines [J].
Moreaux, Jerome ;
Klein, Bernard ;
Bataille, Regis ;
Descamps, Geraldine ;
Maiga, Sophie ;
Hose, Dirk ;
Goldschmidt, Hartmut ;
Jauch, Anna ;
Reme, Thierry ;
Jourdan, Michel ;
Amiot, Martine ;
Pellat-Deceunynck, Catherine .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (04) :574-582
[35]   Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805) [J].
Kim, Kihyun ;
Kim, Jin Seok ;
Yoon, Sung-Soo ;
Yoon, Dok Hyun ;
Eom, Hyeon-Seok ;
Lee, Je-Jung ;
Yim, Hyeon Woo ;
Park, Misun ;
Lee, Hojoon ;
Min, Chang-Ki .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (01) :110-121
[36]   Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation [J].
Alsina, Melissa ;
Becker, Pamela S. ;
Zhong, Xiaobo ;
Adams, Alexia ;
Hari, Parameswaran ;
Rowley, Scott ;
Stadtmauer, Edward A. ;
Vesole, David H. ;
Logan, Brent ;
Weisdorf, Daniel ;
Qazilbash, Muzaffar ;
Popplewell, Leslie L. ;
McClune, Brian ;
Bensinger, William ;
Riches, Marcie ;
Giralt, Sergio A. ;
Pasquini, Marcelo C. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (08) :1183-1189
[37]   Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805) [J].
Kihyun Kim ;
Jin Seok Kim ;
Sung-Soo Yoon ;
Dok Hyun Yoon ;
Hyeon-Seok Eom ;
Je-Jung Lee ;
Hyeon Woo Yim ;
Misun Park ;
Hojoon Lee ;
Chang-Ki Min .
International Journal of Hematology, 2022, 116 :110-121
[38]   Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia [J].
Felipe Combariza, Juan ;
Orduz, Rocio ;
Agudelo, Claudia ;
Hernandez, Sonia ;
Maria Madera, Ana ;
Leon, Guillermo ;
Avila, Vladimir ;
Bautista, Leonardo ;
Valdes, Jaime ;
Camargo, Carlos ;
Sanchez, Victor ;
Mejia, Fabian ;
Moreno, Liliana ;
Ramirez, Carlos .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08) :601-607
[39]   PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma [J].
Bai, Hua ;
Zhu, Yudi ;
Xu, Peipei ;
Chen, Bing .
BIOMED RESEARCH INTERNATIONAL, 2020, 2020
[40]   How I treat high-risk myeloma [J].
Lonial, Sagar ;
Boise, Lawrence H. ;
Kaufman, Jonathan .
BLOOD, 2015, 126 (13) :1536-1543
12345